FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056599701> ?p ?o ?g. }

• W2056599701 endingPage "10" @default.
• W2056599701 startingPage "7" @default.
• W2056599701 abstract "Newer, more effective statins are powerful agents for reducing elevated levels of low-density lipoprotein (LDL) cholesterol and thereby lowering the risk of coronary heart disease (CHD) and related adverse events. Although LDL remains the primary target of therapy for reducing CHD risk, increased interest is focusing on apolipoprotein B (apoB)-containing lipoprotein subfractions—particularly very-low-density lipoprotein (VLDL), VLDL remnants, and intermediate-density lipoproteins (IDL)—as secondary targets of therapy. Elevated apoB is known to be an important risk factor for CHD, and dysregulation of the metabolism of apoB-containing lipoproteins is involved in the progression of atherosclerosis. Statins reduce circulating concentrations of atherogenic apoB-containing lipoproteins by decreasing the production of VLDL in the liver and, thus, the production of VLDL remnants and LDL. Statins also increase the clearance of these particles through upregulation of LDL receptors in the liver. Efforts to develop statins with enhanced lipid-modifying properties are ongoing. The optimal statin would offer a high degree of inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a prolonged duration of action, hepatic selectivity for maximal upregulation of LDL receptors, and a low potential for drug–drug interactions. Recent studies have shown that rosuvastatin, a new agent in this class, demonstrates these qualities. Rosuvastatin is a highly effective inhibitor of HMG-CoA reductase, is relatively nonlipophilic, has a half-life of approximately 20 h, exhibits hepatic selectivity, has little systemic availability, and has a low potential for drug–drug interactions because of its limited degree of metabolism by the cytochrome P-450 system. A recent double-blind, crossover study revealed that treatment with rosuvastatin resulted in marked reductions in apoB-containing lipoproteins in patients with type IIa or IIb dyslipidemia. By reducing the number of atherogenic lipoprotein particles, rosuvastatin decreases the atherosclerotic burden in hyperlipidemic patients at high risk for CHD and related adverse outcomes." @default.
• W2056599701 created "2016-06-24" @default.
• W2056599701 creator A5003522491 @default.
• W2056599701 creator A5041604889 @default.
• W2056599701 creator A5061389868 @default.
• W2056599701 creator A5081692228 @default.
• W2056599701 date "2003-01-01" @default.
• W2056599701 modified "2023-09-27" @default.
• W2056599701 title "New dimension of statin action on apoB atherogenicity" @default.
• W2056599701 cites W1485967434 @default.
• W2056599701 cites W1966936568 @default.
• W2056599701 cites W1975877182 @default.
• W2056599701 cites W1983249702 @default.
• W2056599701 cites W1984603222 @default.
• W2056599701 cites W1986343000 @default.
• W2056599701 cites W1988933958 @default.
• W2056599701 cites W1989958072 @default.
• W2056599701 cites W2033511358 @default.
• W2056599701 cites W2043233190 @default.
• W2056599701 cites W2044142881 @default.
• W2056599701 cites W2067236087 @default.
• W2056599701 cites W2075899490 @default.
• W2056599701 cites W2084744450 @default.
• W2056599701 cites W2103995568 @default.
• W2056599701 cites W2106536809 @default.
• W2056599701 cites W2107841008 @default.
• W2056599701 cites W2118310760 @default.
• W2056599701 cites W2129750583 @default.
• W2056599701 cites W2143465004 @default.
• W2056599701 cites W2149677053 @default.
• W2056599701 cites W2152789823 @default.
• W2056599701 cites W2155598961 @default.
• W2056599701 cites W2158205132 @default.
• W2056599701 cites W2322095705 @default.
• W2056599701 cites W2498728061 @default.
• W2056599701 cites W2607031541 @default.
• W2056599701 cites W4238251256 @default.
• W2056599701 cites W4252142357 @default.
• W2056599701 doi "https://doi.org/10.1002/clc.4960261304" @default.
• W2056599701 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6653840" @default.
• W2056599701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12539816" @default.
• W2056599701 hasPublicationYear "2003" @default.
• W2056599701 type Work @default.
• W2056599701 sameAs 2056599701 @default.
• W2056599701 citedByCount "22" @default.
• W2056599701 countsByYear W20565997012012 @default.
• W2056599701 countsByYear W20565997012015 @default.
• W2056599701 countsByYear W20565997012016 @default.
• W2056599701 countsByYear W20565997012017 @default.
• W2056599701 countsByYear W20565997012018 @default.
• W2056599701 countsByYear W20565997012019 @default.
• W2056599701 countsByYear W20565997012020 @default.
• W2056599701 countsByYear W20565997012021 @default.
• W2056599701 countsByYear W20565997012022 @default.
• W2056599701 countsByYear W20565997012023 @default.
• W2056599701 crossrefType "journal-article" @default.
• W2056599701 hasAuthorship W2056599701A5003522491 @default.
• W2056599701 hasAuthorship W2056599701A5041604889 @default.
• W2056599701 hasAuthorship W2056599701A5061389868 @default.
• W2056599701 hasAuthorship W2056599701A5081692228 @default.
• W2056599701 hasBestOaLocation W20565997012 @default.
• W2056599701 hasConcept C104950815 @default.
• W2056599701 hasConcept C126322002 @default.
• W2056599701 hasConcept C134018914 @default.
• W2056599701 hasConcept C134651460 @default.
• W2056599701 hasConcept C181199279 @default.
• W2056599701 hasConcept C185592680 @default.
• W2056599701 hasConcept C2776839432 @default.
• W2056599701 hasConcept C2778163477 @default.
• W2056599701 hasConcept C2779620165 @default.
• W2056599701 hasConcept C2780072125 @default.
• W2056599701 hasConcept C2780499067 @default.
• W2056599701 hasConcept C43554185 @default.
• W2056599701 hasConcept C55493867 @default.
• W2056599701 hasConcept C62746215 @default.
• W2056599701 hasConcept C71924100 @default.
• W2056599701 hasConcept C8243546 @default.
• W2056599701 hasConcept C98274493 @default.
• W2056599701 hasConceptScore W2056599701C104950815 @default.
• W2056599701 hasConceptScore W2056599701C126322002 @default.
• W2056599701 hasConceptScore W2056599701C134018914 @default.
• W2056599701 hasConceptScore W2056599701C134651460 @default.
• W2056599701 hasConceptScore W2056599701C181199279 @default.
• W2056599701 hasConceptScore W2056599701C185592680 @default.
• W2056599701 hasConceptScore W2056599701C2776839432 @default.
• W2056599701 hasConceptScore W2056599701C2778163477 @default.
• W2056599701 hasConceptScore W2056599701C2779620165 @default.
• W2056599701 hasConceptScore W2056599701C2780072125 @default.
• W2056599701 hasConceptScore W2056599701C2780499067 @default.
• W2056599701 hasConceptScore W2056599701C43554185 @default.
• W2056599701 hasConceptScore W2056599701C55493867 @default.
• W2056599701 hasConceptScore W2056599701C62746215 @default.
• W2056599701 hasConceptScore W2056599701C71924100 @default.
• W2056599701 hasConceptScore W2056599701C8243546 @default.
• W2056599701 hasConceptScore W2056599701C98274493 @default.
• W2056599701 hasIssue "S1" @default.
• W2056599701 hasLocation W20565997011 @default.
• W2056599701 hasLocation W20565997012 @default.

• next